702 related articles for article (PubMed ID: 17561317)
1. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
[TBL] [Abstract][Full Text] [Related]
2. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
Huang Y; Cyr SL; Burt DS; Anderson R
J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
[TBL] [Abstract][Full Text] [Related]
3. C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine.
Cyr SL; Jones T; Stoica-Popescu I; Burt D; Ward BJ
Vaccine; 2007 Apr; 25(16):3228-32. PubMed ID: 17374422
[TBL] [Abstract][Full Text] [Related]
4. TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model.
Cyr SL; Angers I; Guillot L; Stoica-Popescu I; Lussier M; Qureshi S; Burt DS; Ward BJ
Vaccine; 2009 Jan; 27(3):421-30. PubMed ID: 19013492
[TBL] [Abstract][Full Text] [Related]
5. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
[TBL] [Abstract][Full Text] [Related]
6. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
[TBL] [Abstract][Full Text] [Related]
7. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus.
Valosky J; Hishiki H; Zaoutis TE; Coffin SE
Clin Diagn Lab Immunol; 2005 Jan; 12(1):171-9. PubMed ID: 15643003
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles.
Harcourt JL; Anderson LJ; Sullender W; Tripp RA
Vaccine; 2004 Jun; 22(17-18):2248-60. PubMed ID: 15149784
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary T cells induced by respiratory syncytial virus are functional and can make an important contribution to long-lived protective immunity.
Ostler T; Ehl S
Eur J Immunol; 2002 Sep; 32(9):2562-9. PubMed ID: 12207340
[TBL] [Abstract][Full Text] [Related]
10. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.
Mottram PL; Leong D; Crimeen-Irwin B; Gloster S; Xiang SD; Meanger J; Ghildyal R; Vardaxis N; Plebanski M
Mol Pharm; 2007; 4(1):73-84. PubMed ID: 17274665
[TBL] [Abstract][Full Text] [Related]
11. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
[TBL] [Abstract][Full Text] [Related]
12. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
Johnson TR; Graham BS
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
[TBL] [Abstract][Full Text] [Related]
13. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
[TBL] [Abstract][Full Text] [Related]
14. Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge.
Etchart N; Baaten B; Andersen SR; Hyland L; Wong SY; Hou S
Eur J Immunol; 2006 May; 36(5):1136-44. PubMed ID: 16619288
[TBL] [Abstract][Full Text] [Related]
15. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein.
Bembridge GP; Garcia-Beato R; López JA; Melero JA; Taylor G
J Immunol; 1998 Sep; 161(5):2473-80. PubMed ID: 9725246
[TBL] [Abstract][Full Text] [Related]
16. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
[TBL] [Abstract][Full Text] [Related]
17. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection.
Kim S; Jang JE; Yu JR; Chang J
Vaccine; 2010 May; 28(22):3801-8. PubMed ID: 20362203
[TBL] [Abstract][Full Text] [Related]
18. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.
Zeng R; Qi X; Gong W; Mei X; Wei L; Ma C; Yin X
Vaccine; 2007 Oct; 25(42):7422-8. PubMed ID: 17850930
[TBL] [Abstract][Full Text] [Related]
19. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation.
Stegmann T; Kamphuis T; Meijerhof T; Goud E; de Haan A; Wilschut J
Vaccine; 2010 Aug; 28(34):5543-50. PubMed ID: 20600502
[TBL] [Abstract][Full Text] [Related]
20. Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection.
Hussell T; Georgiou A; Sparer TE; Matthews S; Pala P; Openshaw PJ
J Immunol; 1998 Dec; 161(11):6215-22. PubMed ID: 9834108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
